The Gläsernes Labor Akademie (GLA) and the Verband Biologie, Biowissenschaften und Biomedizin in Deutschland (VBIO e.V.) are offering the "Biotech & Pharma Business Summer School - from Target to Market" again this year. From 30 August to 02 September 2023, the orientation course will provide young professionals who are thinking about starting a career in drug development or are already working there with a compact overview of the overall industry process of drug development, including its complex regulatory, legal and organizational requirements.
In biomedical research, the identification of a "target", i.e. a site to bind for an active ingredient against a specific disease, usually marks the starting point for the development of a new drug. However, most development candidates do not make it to market approval. On average, it takes 12 years and costs the manufacturer more than 1 billion euros until a new drug is released for the first patients.
The planning, execution and evaluation of studies in the many stages of preclinical and clinical development in front of highest regulatory requirements and global competition require an efficient interaction of international teams and newest technology. The complexity of modern drug development poses challenges and risks, but also offers many career prospects for young scientists from the life sciences.
The aim of this course is to provide a solid understanding of the individual phases of drug development and thus enable the attendees to orient themselves in potential fields of activity in biotechnology and the pharmaceutical industry.
The trainer team of the "Biotech & Pharma Business Summer School" consists of experts from the pharmaceutical industry, biotech companies, leading Contract Research Organizations (CROs) and from patent attorney offices. They will guide the participants through the various phases of drug development, from the idea to market maturity, with keynote speeches, workshops and a panel discussion. A dinner lecture with Prof. Wolf-Dieter Ludwig, head of the German Medicines Commission, with a critical view of the validity of clinical studies in oncology will round off the seminar program.
The course fee per person is 1.683,00 € plus VAT. Participants from academic institutions pay 1,346.00 € plus VAT; 10% discount for members of VBIO and its professional societies.
For more information visit https://www.glaesernes-labor-akademie.de/de/biotech-pharma .
For further questions please contact Dr. Uwe Lohmeier (email@example.com , Tel: +49 30-9489-2935).